Clayton Borg, MD
Cardiovascular Disease · Little Rock, ARNPI 1427060581
Payments from drug & device makers
Across 620 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Abbott$2K
- Edwards Lifesciences$1K
- AstraZeneca$1K
- Boehringer Ingelheim$944
- Pfizer$943
- plus $5K from 27 others
What the payments were for
- Travel & lodging$320%
- Food & beverage$14,13298%
- Education$2141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 184 | $2,849 |
| Abbott | 57 | $2,293 |
| Edwards Lifesciences | 15 | $1,210 |
| AstraZeneca | 47 | $1,008 |
| Boehringer Ingelheim | 51 | $944 |
| Pfizer | 53 | $943 |
| Boston Scientific | 20 | $813 |
| Amgen | 40 | $644 |
| Johnson & Johnson | 41 | $624 |
| Medtronic | 5 | $519 |
| Heartflow, Inc. | 5 | $320 |
| E.r. Squibb & Sons, L.L.C. | 19 | $295 |
| Sanofi-aventis U.S. LLC | 15 | $268 |
| GE HealthCare | 6 | $224 |
| Alnylam Pharmaceuticals Inc. | 13 | $210 |
| Novo Nordisk | 6 | $187 |
| Abiomed | 2 | $145 |
| Astellas Pharma US Inc | 3 | $145 |
| Lantheus Medical Imaging, Inc. | 7 | $132 |
| Esperion Therapeutics, Inc. | 2 | $113 |
| Irhythm Technologies, Inc. | 6 | $89 |
| Merck | 4 | $73 |
| Bridgebio Pharma, Inc. | 3 | $65 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $43 |
| Akcea Therapeutics, Inc. | 2 | $39 |
| United Therapeutics Corporation | 2 | $38 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Lexicon Pharmaceuticals, Inc. | 2 | $29 |
| Cardiva Medical, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| CMP Pharma, Inc. | 1 | $14 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$478
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$363
- Edwards SAPIEN 3 Transcatheter Heart Valve$264
- JARDIANCE$254
- Mitra Clip system$242
- FFRct$240
- CoreValve Evolut$152
- COREVALVE EVOLUT R$141
- Ozempic$124
- ENTRESTO$121
- Impella$115
- VYNDAQEL$114
- Sentinel$105
- LEQVIO$103
- GENERAL - STRUCTURAL HEART$101
- BRILINTA$100
How this compares
$14,378 in reported general payments places this provider in the 75th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 557 | $468,496 |
| EntrestoSacubitril/Valsartan | 325 | $295,171 |
| XareltoRivaroxaban | 232 | $195,683 |
| FarxigaDapagliflozin Propanediol | 178 | $138,033 |
| MultaqDronedarone Hcl | 103 | $88,494 |
| JardianceEmpagliflozin | 67 | $48,720 |
| Repatha SureclickEvolocumab | 73 | $43,816 |
| Metoprolol Succinate | 1,008 | $15,147 |
| Praluent PenAlirocumab | 24 | $14,842 |
| OzempicSemaglutide | 13 | $11,783 |
| Atorvastatin Calcium | 830 | $7,582 |
| Rosuvastatin Calcium | 613 | $7,224 |
| Valsartan | 312 | $6,883 |
| Ranolazine ErRanolazine | 69 | $4,417 |
| Verapamil SrVerapamil Hcl | 42 | $3,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $943 | $468,496557 claims |
| NovartisEntresto | $2,849 | $295,171325 claims |
| Johnson & JohnsonXarelto | $624 | $195,683232 claims |
| AstraZenecaFarxiga | $1,008 | $138,033178 claims |
| Sanofi-aventis U.S. LLCMultaq | $268 | $88,494103 claims |
| Boehringer IngelheimJardiance | $944 | $48,72067 claims |
| Novo NordiskOzempic | $187 | $11,78313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$1.1M
- Christian Assad KottnerLittle Rock$670K
- Barry UretskyLittle Rock$609K
- William RollefsonLittle Rock$512K
- David JonesLittle Rock$473K
- Joe HargroveLittle Rock$464K
- Freddy ChrismanLittle Rock$283K
- Andre PaixaoLittle Rock$176K
- David MegoLittle Rock$123K
- Daniel SherbetLittle Rock$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.